Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Focus of Regulatory Concerns Regarding Pharmacometric Review in the Development and Evaluation of Antimicrobial Agents
  • +7
  • Dong Yang,
  • Ming Zhao,
  • Cheng Lyu,
  • Xingchen Bian,
  • Xin Li,
  • Weiyi Qiu,
  • Zhiwei Huang,
  • Yuancheng Chen,
  • Zijian Hu,
  • Jing Zhang
Dong Yang
Covance Pharmaceutical Research and Development (Beijing) Co. Limited

Corresponding Author:[email protected]

Author Profile
Ming Zhao
China Food and Drug Administration
Author Profile
Cheng Lyu
Shanghai LianBio Development Co., Ltd.
Author Profile
Xingchen Bian
Fudan University Huashan Hospital Institute of Antibiotics
Author Profile
Xin Li
Fudan University Huashan Hospital Institute of Antibiotics
Author Profile
Weiyi Qiu
Beijing Institute of Biotechnology
Author Profile
Zhiwei Huang
Fudan University Huashan Hospital Institute of Antibiotics
Author Profile
Yuancheng Chen
Huashan Hospital Fudan University
Author Profile
Zijian Hu
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
Author Profile
Jing Zhang
Fudan University Huashan Hospital Institute of Antibiotics
Author Profile

Abstract

Pharmacometrics is an emerging science that interprets drug, disease and trial information in a mathematical fashion to inform and facilitate efficient drug development and/or regulatory decisions. Pharmacometric study is increasingly adopted in the regulatory review of new antimicrobial agents. We summarized and reviewed the 31 antimicrobial agents approved by the US Food and Drug Administration (FDA) and the 26 antimicrobial agents approved by European Medicines Agency (EMA) from January 2001 to May 2019. Regulatory concerns in pharmacometric review of antimicrobial agents were expounded with examples, including modeling and simulation methods, effects of internal/external factors on PK parameters, safety and efficacy evaluation in terms of exposure-response analysis, refinement of the wording of product labeling and package leaflet, and possible post-marketing clinical trial. Ongoing communication among regulators, academia, and industry regarding pharmacometrics is encouraged to streamline and facilitate the development of new antimicrobial agents. The industry can maximize its benefit in drug development through continued pharmacometric education/training.